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Key messages
What is already known about this subject?
 ► Epithelial removal in epithelium-off corneal colla-
gen cross-linking (CXL) may predispose to microbial 
keratitis.
 ► Although the use of bandage contact lens and topical 
steroids is useful in the postoperative care, reducing 
pain and inflammation, there is currently insufficient 
evidence to which extent they may predispose to the 
incidence of microbial keratitis.
What are the new findings?
 ► The results of our study, which is the largest to date 
series on microbial keratitis following epithelium-off 
CXL, demonstrate that postoperative treatment pro-
tocol plays a substantial role in preventing this pos-
sibly sight-threatening complication.
How might these results change the focus of 
research or clinical practice?
 ► The use of bandage contact lens and topical steroids 
in the early postoperative period may increase the 
risk of developing microbial keratitis and should be 
avoided in terms of safety.
AbsTrACT
Objective To investigate the role of bandage contact 
lenses (BCL) and topical steroids as risk factors for the 
development of microbial keratitis after epithelium-off 
corneal collagen cross-linking (CXL).
Methods and Analysis Patients undergoing CXL 
between February 2011 and July 2017 were included. 
Patients were divided into two groups: those who were 
treated postoperatively with a BCL, topical antimicrobial 
and steroids (group 1) and those who received only a 
topical antimicrobial until healing of the epithelial defect 
before introduction of topical steroids (group 2).
results 1273 eyes of 964 patients were included. Group 
1 comprised 316 eyes and group 2 comprised 957 eyes. 
There were no significant differences in the presence 
of persisting corneal haze or scarring between the two 
groups (p=0.57). Microbial keratitis occurred in nine eyes 
(0.71% of eyes) of eight (0.83%) patients (one case was 
bilateral) out of 1273 eyes. Staphylococcus aureus was 
cultured from corneal scrapes in seven out of nine (77.8%) 
cases and from contiguous sites in the two cases. All 
cases occurred in group 1 (incidence=2.85%) and none in 
group 2 (p<0.0001). A greater proportion of patients who 
developed microbial keratitis were atopic (75%, p=0.4).
Conclusion The use of BCL and topical steroids prior 
to healing of the epithelium is a significant risk factor for 
microbial keratitis. S. aureus is the most common micro-
organism and is likely to originate from an endogenous 
site. Not using a BCL and delaying the introduction of 
topical steroids until epithelial healing significantly reduce 
the risk of developing microbial keratitis without increasing 
the risk of persistent corneal haze.
InTrOduCTIOn
Introduced by Wollensak et al in 2003, corneal 
collagen cross-linking (CXL) has become 
accepted as a useful technique to reduce the 
risk of progression of keratoconus and other 
types of corneal ectasia.1 2 Previous reports 
have demonstrated the efficacy of CXL to 
stabilise disease progression, to prevent dete-
rioration of vision and to reduce the need for 
corneal transplantation.3–6
Although there are several reports of 
performing CXL with an intact epithelium 
(transepithelial or epithelium-on), CXL 
with epithelial removal (epithelium-off) is 
still considered to be the gold standard of 
treatment.1 2 6 7 Removal of the epithelium, 
however, is associated with a significant risk of 
epithelial healing problems and may increase 
the risk of corneal infections, as one of the 
main physical barriers to microbes and other 
pathogens is removed.8 9 Indeed, the devel-
opment of microbial keratitis (MK) is one 
of the most serious complications following 
CXL.10 11
Several risk factors for the development of 
microbial keratitis following CXL have been 
proposed.8–11 These include the presence of 
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an epithelial defect, use of a bandage contact lens (BCL), 
conditions that may prolong the epithelium healing 
process such as atopic conjunctivitis, diabetes mellitus 
or the use of anaesthetic eye-drops, and postoperative 
steroid use.8–11 There is also the potential temporary 
loss of immune cells in the cornea following treatment. 
In this study, we investigated the incidence of microbial 
keratitis in patients undergoing epithelium-off CXL for 
keratoconus with and without postoperative BCL and 
steroids, and associated micro-organisms.
PATIenTs And MeTHOds
All patients who had undergone CXL for keratoconus 
from February 2011 to July 2017 at The Royal Liver-
pool University Hospital, UK were included. The main 
criterion for patients being offered CXL was an evident 
progression of keratoconus demonstrated by a change in 
the curvature within the cone area of at least 1 dioptre (D) 
on instantaneous map when measured at least 3 months 
apart. Exclusion criteria for CXL were minimal corneal 
pachymetry of less than 380 µm, recent history of corneal 
infection, concomitant ocular or systemic autoimmune 
disease, and pregnancy or breast feeding. A corneal infil-
trate with an overlying epithelial defect, ocular discharge, 
anterior chamber inflammatory reaction, conjunctival 
injection and subjective symptoms were considered as 
clinically suspected microbial keratitis.
We previously described the CXL protocol used in our 
centre. Briefly, it involves removal of corneal epithelium 
with 20% alcohol followed by 15 min of 0.1% riboflavin 
(VibeX Rapid).12 Corneas were irradiated with Ultraviolet 
A 365 nm light using Avedro’s KXL (Avedro, Massachu-
setts, USA) machine at an irradiance of 6 mW/cm2 for 15 
min, delivering a total of 5.4 J/cm2. The CXL procedures 
were performed in an aseptic room specially designed 
and used for CXL following strict hygiene and sterili-
sation rules. All instruments and materials used during 
each procedure were sterile, and povidone iodine was 
applied prior to CXL both to the conjunctival fornices 
(5%) as well as to the surrounding skin (10%).
Patients were divided into two groups according to 
the postoperative treatment that they received. Group 
1 included cases in which postoperative management 
consisted of chloramphenicol 0.5% eye-drops every 2 
hours for the first 2 days and then four times a day for 1 
week, the use of a BCL (SB18, Menicon) and dexametha-
sone 0.1% eye-drops four times a day for 1 month starting 
from day 1. Patients were reviewed on days 2 and 7 and 
the BCL was removed subject to satisfactory epithelial 
healing. In group 2, patients received chloramphenicol 
1% preservative-free ointment 2 hourly for the first 2 days 
and then four times a day for 1 week, followed by 0.1% 
dexamethasone eye-drops four times daily for 1 month. 
All patients were reviewed 2 and 7 days after CXL.
In patients who developed a clinically suspected 
microbial keratitis following CXL, corneal scrapes were 
collected for smear and culture. Swabs were also taken 
from the conjunctival fornices, anterior nares and 
pharyngeal arches for possible endogenous sources of 
infection. Patients were commenced on 1% teicoplanin 
eye-drops and 0.3% ciprofloxacin ointment hourly for 
24 hours and then hourly only during waking hours 
according to the clinical response and microbiolog-
ical results. Possible risk factors were recorded in every 
case and data were enrolled in a multivariate analysis. 
Confocal microscopy was performed in all cases.
Statistical analysis was performed with MedCalc Statis-
tical Software V.14.8.1 (MedCalc Software bvba, Ostend, 
Belgium) and SPSS V.19.0 for Windows. Data are given as 
mean±SD. Normality was checked using the Kolmogor-
ov-Smirnov test. When parametric analysis was possible, 
the Student’s t-test was used to compare the outcomes 
between two independent samples. Categorical variables 
were compared using the Fisher’s exact probability test. 
Non-parametric Kruskal-Wallis and Mann-Whitney tests 
were also used to examine the associations between cate-
gorical variables and continuous or ordered outcomes. 
A binary logistic regression model was used to test the 
proposed risk factors for significance. A p value of <0.05 
was considered significant.
resulTs
The study included 1273 eyes of 964 patients treated 
with epithelium-off CXL between February 2011 and July 
2017: 316 eyes of 215 patients (47% of bilateral treat-
ment) in group 1 and 957 eyes of 749 patients (27.8% 
of bilateral treatment) in group 2. There were no signif-
icant differences between the two groups with regard to 
age, gender, atopic history, maximum simulated kerato-
metric values, minimum corneal thickness and history 
of microbial keratitis (table 1). Following treatment, 
there were no significant differences in the presence 
of persisting corneal haze or scarring between the two 
groups (p=0.57), when cases of microbial keratitis were 
excluded. There were no non-infective-related serious 
adverse events or reactions.
A microbial keratitis occurred in 9 eyes (0.71% of 
eyes) of 8 (0.83%) patients (1 case was bilateral) out 
of 1273 eyes. All the nine cases of microbial keratitis 
occurred in group 1 (incidence of 2.85%) and none in 
group 2 (p<0.0001; table 1). Of the eight patients who 
developed a microbial keratitis, five had undergone 
bilateral simultaneous CXL and three patients had had 
unilateral treatment in one eye only at the time of the 
development of microbial keratitis. The main charac-
teristics of these patients are shown in tables 2 and 3. 
There was a 7:1 male preponderance and the average 
age was 21.5 years (range: 12–28 years). All were diag-
nosed between 1 and 5 days (mean 3.75 days) after 
CXL (table 3). An epithelial defect with surrounding 
infiltrate was present in all cases (figure 1). Six eyes had 
central ulcers (66.7%), and a hypopyon was present in 
three eyes (33.3%). The only type of micro-organism 
isolated was Staphylococcus aureus, which was isolated 
from the cornea in seven cases, from the conjunctiva in 
two patients, the nose in three patients and the pharynx 
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Table 1 Demographics and clinical characteristics data of patients undergoing CXL: comparison between group 1 and group 
2, as well as between total and cases with microbial keratitis (MK)
Group 1 Group 2
P value
(group 1 vs 
group 2) Total
Cases with 
keratitis
P value
(keratitis vs 
total)
Patients (n) 215 749 964 8
Eyes (n) 316 957 1273 9
Age (years) 23.8±6.5 24.3±6.6 0.33* 24.3±6.6 21.5±6 0.23*
Gender (male/female) 138/77 553/196 0.27† 691/273 7/1 0.79†
Atopy 109/215 (50.7%) 354/749 (47.3%) 0.64† 463/964 (48%) 6/8 (75%) 0.4†
Bilateral treatments 101/215 (47%) 208/749 (27.8%) 0.006† 309/964 (32.1%) 1/8 (12.5%) 0.7†
History of MK 2/316 4/957 0.64† 6/1273 0/9 1.0†
Kmax (dioptres) 51.7±6.2 51.2±6.7 0.24* 51.23±6.4 53.2±7 0.36*
Kmean (dioptres) 49.72±5.7 49.39±7.2 0.46* 49.51±5.5 50.32±6.3 0.66*
CCT (μm) 501.3±52 502.7±59 0.71* 502.4±57 492.7±53 0.61*
CTmin (μm) 469.8±53 473.9±49 0.21* 473.6±56 452.5±29 0.26*
Corneal haze/scarring 1/307 (0.3%)‡ 2/957 (0.2%) 0.57†
Microbial keratitis 9/316 (2.85%) 0/957 (0%) 0.000004†
*Assessed with Student’s t-test and Mann-Whitney test.
†Assessed with Fisher’s exact test.
‡Cases with microbial keratitis were excluded in this analysis.
CCT, central corneal thickness; CTmin, minimum corneal thickness; CXL, corneal collagen cross-linking; Kmax, preoperative maximum 
simulated keratometric value; Kmean, preoperative average simulated keratometric value.
Table 2 Detailed demographics of individual cases with microbial keratitis following CXL
Patients Gender Age Kmax (dpt) Kmin (dpt) Kmean (dpt) CTmin (μm)
VA before CXL 
(logMAR)
VA last visit 
(logMAR)
VA change 
(logMAR)
Patient 1 Male 20 47.1 41.3 44.4 454 0.18 0.18 0
Patient 2 Male 14 – – 54.7 487 1 1.3 0.3
Patient 3 Male 23 43.6 41.8 43.4 476 −0.08 −0.18 −0.1
Patient 4 Male 28 64.6 53.3 50.2 486 0.6 0.6 0
Patient 5 Male 12 – – 64.8 412 1.78 1 −0.78
Patient 6 Female 28 49.8 44.8 47.7 463 0.3 0.18 −0.12
Patient 6 Female 28 55.8 46.0 49.7 447 0.18 0.3 0.12
Patient 7 Male 21 57.0 50.9 48.5 445 0.3 0.78 0.48
Patient 8 Male 26 54.7 46.0 49.5 403 0.1 0.48 0.38
–, denotes missing or unavailable data; negative VA change denotes an improvement in logMAR acuity from VA before CXL to VA at last visit.
CTmin, minimum corneal thickness; CXL, corneal collagen cross-linking; Kmax, preoperative maximum simulated keratometric value; 
Kmean, preoperative average simulated keratometric value; Kmin, preoperative minimum simulated keratometric value; VA, visual acuity; 
dpt, diopters; logMAR, logarithm of the minimum angle of resolution.
in one patient (table 3). No specific findings were iden-
tified on confocal microscopy. The mean ulcer healing 
time was 5.3 days (range: 2–20 days). The presence 
of atopic disease was higher, although not statistically 
significant (p=0.4), in those patients who developed a 
microbial keratitis (six out of the eight patients, ie, 75%) 
as compared with those who did not (48%). The mean 
change in visual acuity (converting Snellen to logarithm 
of the minimum angle of resolution [logMAR] estimate) 
between pre-CXL and their most recent appointment 
post-CXL was a worsening of 0.3 logMAR (an improve-
ment of −0.78 logMAR at best and a worsening of 0.48 
logMAR at worst). No case of reduced compliance to 
the postoperative treatment protocol was noted among 
patients with keratitis.
Age, gender, preoperative minimum corneal thickness, 
history of atopic disease, bilaterality of treatment and 
preoperative maximum simulated keratometric value 
were not found to be significant risk factors associated 
with the development of microbial keratitis (table 4). 
The only variable that yielded statistical significance was 
the use of BCL and steroids before epithelial healing 
(p=0.005).
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Figure 1 Corneal photographs of eyes with post-CXL 
keratitis. The left image shows a central corneal ulcer with 
infiltrate (case 3), while the right image shows a small early 
inferior paracentral corneal ulcer with respective infiltrate 
(case 6). CXL, corneal collagen cross-linking.
Table 4 Univariate analysis of the association between risk 
factors and development of microbial keratitis after CXL
OR 95% CI P value
Age 0.95 0.85 to 1.07 0.38
Atopy 3.68 0.76 to 17.79 0.07
CTmin 0.99 0.98 to 1.00 0.26
Gender 0.73 0.15 to 3.53 0.69
Bilateral treatment 0.3 0.04 to 2.45 0.26
Postoperative BCL 
and steroids use
58.78 3.41 to 1012.89 0.005
Kmax 1.09 0.97 to 1.23 0.15
BCL, bandage contact lens; CTmin, minimum preoperative corneal 
thickness; CXL, corneal collagen cross-linking; Kmax, maximum 
preoperative keratometric value.
dIsCussIOn
Although CXL is considered a relatively safe procedure, 
rare but sight-threatening complications may occur, 
including microbial keratitis, presumed sterile corneal 
infiltrates, corneal melting, corneal haze, scarring, 
herpes simplex virus keratitis and corneal endothelial 
damage.10 11 13–20 Until modifications can be made to 
improve the efficacy of transepithelial CXL, removal of 
the corneal epithelial barrier remains a risk factor for the 
development of microbial keratitis following standard 
CXL treatment.
Previous reports have identified poor postoperative 
treatment compliance and hygiene and the use of a BCL 
as possible risk factors for the development of microbial 
keratitis following CXL.8–11 17 18 Maharana et al21 published 
a case series of seven microbial keratitis cases (incidence 
1.3%) after accelerated CXL with the use of a BCL, and 
concluded that younger age, atopic history, poor compli-
ance and postoperative treatment may contribute to the 
development of keratitis.21 It is likely that changes in 
ocular flora and the use of topical steroids in patients with 
atopic or vernal conjunctivitis further increase the risk 
of postoperative keratitis.22 Shetty et al11 used a regimen 
in which a BCL was placed at the end of treatment, but 
steroids were deferred until epithelial healing had taken 
place.11 Despite the deferral of steroids, four patients still 
developed microbial keratitis, suggesting the BCL may 
have been a greater risk factor for the development of 
microbial keratitis relative to the use of steroids.
The results of our study, which represents the largest 
up-to-date cohort on microbial keratitis following CXL, 
indicate that not using a BCL and withholding the use 
of topical steroids until the epithelium had healed after 
CXL (usually 2–5 days) were not associated with any 
cases of microbial keratitis. The limitations of the present 
study include its retrospective nature and the lack of a 
comparative measure of postoperative pain evaluation 
between the two study groups. Furthermore, due to the 
retrospective design of the study, it is not possible to 
discern whether the use of BCL, topical steroids or their 
combination has led to the increase in the incidence of 
microbial keratitis. Both of them have been identified 
so far in the literature as possible risk factors for the 
development of microbial keratitis after CXL.10 11 17–21 
In all of the cases described in the systematic review of 
Abbouda et al,10 the postoperative treatment included 
steroids, and in most of them also the use of a BCL. 
In two large retrospective cohorts using a BCL in all 
patients but deferring the use of steroids until complete 
epithelial healing, the incidence of MK after CXL varied 
between 0.17% (4/2350) and 1.3% (7/532). Further 
prospective randomised studies are needed in order to 
independently evaluate the risk and benefits of postop-
erative use of topical steroids and BCL.
It is of note that, in the original description, Wollensak 
et al1 did not describe the use of either topical steroid nor 
of a BCL, but rather only topical antimicrobial therapy 
until the epithelium had healed. The results of this study 
would support that view. A variety of micro-organisms have 
been reported in cases of post-CXL microbial keratitis, 
with the spectrum including Escherichia coli, Aspergillus 
fumigatus, Pseudomonas aeruginosa, Streptococcus and Staph-
ylococcus species, as well as Acanthamoeba spp.,17–21 herpes 
simplex virus and fungi.10 It is of note, therefore, that in 
this study and in contrast to these reports, S. aureus was 
the only micro-organism isolated. In fact, S. aureus was 
cultured from corneal scrapes in seven out of nine cases 
and from contiguous sites in the remaining two cases. 
The clinical features in these two cases were consistent 
with microbial keratitis rather than sterile infiltrates.
Infections with S. aureus usually arise from endogenous 
sources and nasopharyngeal colonisation with S. aureus is 
a well-recognised risk factor.23–25 Approximately 20% of 
the healthy human population are persistently colonised 
with S. aureus and the same strain can persist over months 
or years.26 27 A key feature of non-ocular S. aureus infec-
tion is its recurrence, which occurs in approximately 30% 
of all cases.28 29 It is also of importance to note that S. 
aureus has been found to be associated with recurrent 
microbial keratitis significantly more frequently than 
with other bacteria.30 In addition to the nose, in some 
of our patients S. aureus was isolated from the ipsilateral 
conjunctiva. It is possible, therefore, that S. aureus may 
have persisted at or around the conjunctiva or lid margin 
in these patients as small colony variants,29 as these have 
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been associated with persistent and recurrent infections 
at other sites.31 32
Persistent carriage of S. aureus in patients with kerato-
conus might therefore predispose these individuals to 
recurrent keratitis, especially in those with ocular surface 
disease such as atopic conjunctivitis, which was present 
in six of the eight patients who developed microbial 
keratitis. In patients with atopic or other ocular surface 
disease who are at an increased risk of microbial kera-
titis, collection of samples from the nose and conjunctiva 
prior to CXL followed by S. aureus decolonisation treat-
ment prior to surgery is a consideration.
Interestingly, the combination of a large diameter BCL, 
antibiotics and steroids is often the treatment regimen 
of patients undergoing photorefractive keratectomy 
(PRK), and yet the keratitis rates in this group have been 
reported to be much lower, even less than 0.02%.33 34 
As a matter of fact, Yuksel et al35 have reported compa-
rable colonisation rates of BCLs after PRK and CXL, 
with coagulase-negative staphylococci being the most 
frequent micro-organism.35 Although CXL can also have 
a presumed antimicrobial effect on corneal stroma, the 
difference in microbial keratitis rates could be attributed 
to variations in aseptic surgical conditions and, moreover, 
to the increased incidence of atopy among patients with 
keratoconus in comparison with subjects undergoing 
refractive surgery.
In conclusion, our results would suggest that not using 
a BCL and delaying the introduction of topical steroids 
until epithelial healing may significantly reduce the risk 
of developing microbial keratitis and do not seem to 
increase the risk of persistent corneal haze. The role of 
preoperative sampling of the conjunctiva and nose and 
prophylactic antimicrobials requires further study.
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